Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand
Lonza Group AG / Key word(s): Personnel
Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand
01.07.2024 / 07:00 CET/CEST
____________________________________________________________
* Wolfgang Wienand commences his tenure as Chief Executive
Officer of Lonza Group
* Albert M. Baehny will retire from Lonza Group following a
transition period
Basel, Switzerland, 1 July 2024 - Wolfgang Wienand joins Lonza
Group today as Chief Executive Officer (CEO). Wolfgang succeeds
Albert M. Baehny, who took on the role of CEO ad interim in
October 2023 and was Chairman of the Board of Directors of Lonza
from 2018 to May 2024. Albert will work with Wolfgang to ensure a
smooth leadership handover before he retires from Lonza this
summer.
Jean-Marc Huët, Chairman of the Board of Directors, Lonza,
commented: "On behalf of the Board, I extend a warm welcome to
Wolfgang as he joins Lonza. Wolfgang brings with him a wealth of
CDMO experience, combined with deep strategic and scientific
expertise. As Wolfgang joins, we look forward to an era of stable
and structured growth under his leadership."
Wolfgang Wienand, Chief Executive Officer, Lonza, commented:
"Having worked in the CDMO industry for almost two decades, I
always had great respect for Lonza's ability to transform and
grow at pace. It is a privilege to join this remarkable company
as CEO. As I commence my journey with Lonza, we are embarking on
a quest to meet and exceed the needs of our customers and their
patients. I am greatly looking forward to working with the team
to build on our strong foundations and create a strategy for us
to deliver continued growth and reach our full potential."
Since 2019, Wolfgang has held the role of CEO at Swiss CDMO,
Siegfried. Wolfgang previously served as Chief Scientific Officer
and then as Chief Strategy Officer in Siegfried's executive
leadership team. Prior to joining Siegfried in 2010, Wolfgang
held a series of positions with increasing seniority at the
German specialty chemicals company Evonik Industries.
About Lonza
Lonza is one of the world's largest healthcare manufacturing
organizations. Working across five continents, our global
community of around 18,000 colleagues helps pharmaceutical,
biotech and nutrition companies to bring their treatments to
market. United by our vision to bring any therapy to life, we
support our customers with a combination of technological
insight, world-class manufacturing, scientific expertise, process
excellence and innovation. Our work enables our customers to
develop and commercialize their therapeutic discoveries, allowing
their patients to benefit from life-saving and life-enhancing
treatments.
Our business is structured to meet our customers' complex needs
across four divisions: Biologics, Small Molecules, Cell & Gene,
and Capsules & Health Ingredients. Our company generated sales of
CHF 6.7 billion with a CORE EBITDA of CHF 2.0 billion in
Full-Year 2023. Find out more at www.lonza.com
Follow @Lonza on LinkedIn
Follow @LonzaGroup on X
Lonza Contact Details
Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283
victoria.morgan@lonza.com
Daniel Buchta
Investor Relations
Lonza Group Ltd
Tel +41 61 316 2985
daniel.buchta@lonza.com
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and
is listed on the SIX Swiss Exchange. It has a secondary listing
on the Singapore Exchange Securities Trading Limited ("SGX-ST").
Lonza Group Ltd is not subject to the SGX-ST's continuing listing
requirements but remains subject to Rules 217 and 751 of the
SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute
forward-looking statements. These statements are based on current
expectations and estimates of Lonza Group Ltd, although Lonza
Group Ltd can give no assurance that these expectations and
estimates will be achieved. Investors are cautioned that all
forward-looking statements involve risks and uncertainty and are
qualified in their entirety. The actual results may differ
materially in the future from the forward-looking statements
included in this news release due to various factors.
Furthermore, except as otherwise required by law, Lonza Group Ltd
disclaims any intention or obligation to update the statements
contained in this news release.
All trademarks belong to Lonza and are registered in CH, US
and/or EU, or belong to their respective third-party owners and
are used only for informational purposes.
Privacy Policy link
To immediately delete all the data
____________________________________________________________
End of Media Release
____________________________________________________________
Language: English
Company: Lonza Group AG
Münchensteinerstrasse 38
4052 Basel
Switzerland
Phone: +4161 316 81 11
Internet: www.lonza.com
ISIN: CH0013841017
Valor: 1384101
Listed: SIX Swiss Exchange
EQS News ID: 1935935
End of News EQS News Service
____________________________________________________________
1935935 01.07.2024 CET/CEST